<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Data on endogenous thrombopoietin (TPO) levels and their regulation in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are sparse </plain></SENT>
<SENT sid="1" pm="."><plain>We examined the plasma TPO level of 85 MDS patients by a sensitive enzyme immunoassay and the platelet expression of TPO receptor (TPO-R) protein, which metabolizes endogenous TPO, in 19 MDS patients with an equilibrium binding assay using 125I-TPO </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients had higher plasma TPO levels (7.0 +/- 9.3 fmol/ml) than 52 <z:mpath ids='MPATH_458'>normal</z:mpath> subjects (P &lt; 0.0001) </plain></SENT>
<SENT sid="3" pm="."><plain>Refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> (RA) patients (n = 39) had higher plasma TPO levels than patients (n = 28) with RA with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t) (P = 0.0002), irrespective of similar platelet counts in these groups </plain></SENT>
<SENT sid="4" pm="."><plain>The plasma TPO level correlated inversely with the platelet count in RA patients (P = 0.0027) but not in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t patients (P = 0.7865) </plain></SENT>
<SENT sid="5" pm="."><plain>These data suggest that the physiological pathway for TPO production and metabolism is conserved, at least partially, in RA, but deranged in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t </plain></SENT>
<SENT sid="6" pm="."><plain>The number of TPO-R per platelet was significantly smaller in 19 MDS patients (17.5 +/- 13.3) than in <z:mpath ids='MPATH_458'>normals</z:mpath> (P = 0.0014), but similar between RA patients and patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t </plain></SENT>
<SENT sid="7" pm="."><plain>Further, the bone marrow megakaryocyte count, determined in 31 MDS patients, was quite similar between RA patients and patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t </plain></SENT>
<SENT sid="8" pm="."><plain>Thus, in addition to <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, a reduced platelet TPO-R number may contribute to elevated plasma TPO levels in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, and a regulatory pathway for circulating TPO other than platelet TPO-R and marrow megakaryocytes, such as blasts expressing TPO-R, may operate in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t </plain></SENT>
</text></document>